

## Zoledronic Acid

<b>Form</b>	4mg/5mL concentrate for solution for infusion												
<b>Reconstitution</b>	Already in solution <b>Dilute further prior to administration</b>												
<b>Compatibility &amp; Stability</b>	Sodium chloride 0.9% Glucose 5%												
<b>Administration</b>	<p><b><u>IV Infusion</u></b> Dilute required dose with 100mL compatible fluid. Give over at least 15 minutes.</p> <table border="1" data-bbox="730 741 1185 943"> <thead> <tr> <th>Dose</th> <th>Volume of concentrate</th> </tr> </thead> <tbody> <tr> <td>5mg</td> <td>6.3mL</td> </tr> <tr> <td>4mg</td> <td>5mL</td> </tr> <tr> <td>3.5mg</td> <td>4.4mL</td> </tr> <tr> <td>3.3mg</td> <td>4.1mL</td> </tr> <tr> <td>3.0mg</td> <td>3.8mL</td> </tr> </tbody> </table>	Dose	Volume of concentrate	5mg	6.3mL	4mg	5mL	3.5mg	4.4mL	3.3mg	4.1mL	3.0mg	3.8mL
Dose	Volume of concentrate												
5mg	6.3mL												
4mg	5mL												
3.5mg	4.4mL												
3.3mg	4.1mL												
3.0mg	3.8mL												
<b>Monitoring</b>	<ul style="list-style-type: none"> <li>• Monitor serum electrolytes, calcium, phosphate and magnesium.</li> <li>• Monitor renal function.</li> </ul>												
<b>Additional Information</b>	Patients must be maintained well hydrated prior to and following administration.												

**Information provided relates to Zoledronic Acid manufactured by Mylan**

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542*